References
Aerts JM,
Hollak CE,
Boot RG et al.
(2006)
Substrate reduction therapy of glycosphingolipid storage disorders.
Journal of Inherited Metabolic Disease
29:
449–456.
Alber T
(1989)
Mutational effects on protein stability.
Annual Review of Biochemistry
58:
765–798.
Brown CA and
Mahuran DJ
(1993)
β‐Hexosaminidase isozymes from cells co‐transfected with α and β cDNA constructs: analysis of α subunit missense mutation associated with the adult form of Tay‐Sachs disease.
American Journal of Human Genetics
53:
497–508.
Cachon‐Gonzalez MB,
Wang SZ,
Lynch A et al.
(2006)
Effective gene therapy in an authentic model of Tay‐Sachs‐related diseases.
Proceedings of the National Academy of Sciences of the USA
103:
10373–10378.
Chen B,
Rigat B,
Curry C et al.
(1999)
Structure of the GM2A gene: identification of an exon 2 nonsense mutation and a naturally occurring transcript with an in‐frame deletion of exon 2.
American Journal of Human Genetics
65:
77–87.
Clarke JTR,
Mahuran DJ,
Sathe S et al.
(2010) Open‐label phase I/II clinical trial of pyrimethamine for the treatment of chronic GM2 gangliosidosis. Molecular Genetics and Metabolism (in press).
Conzelmann E and
Sandhoff K
(1978)
AB variant of infantile GM2 gangliosidosis: deficiency of a factor necessary for stimulation of hexosaminidase A‐catalyzed degradation of ganglioside GM2 and glycolipid GA2.
Proceedings of the National Academy of Sciences of the USA
75:
3979–3983.
Desnick RJ
(2004)
Enzyme replacement and enhancement therapies for lysosomal diseases.
Journal of Inherited Metabolic Disease
27:
385–410.
Dill KD and
Shortle D
(1991)
Denatured states of proteins.
Annual Review of Biochemistry
60:
795–825.
Edgington SM
(1992)
Rites of passage: moving biotech proteins through the ER.
Biotechnology
10:
1413–1420.
Gravel RA,
Clarke JTR,
Kaback MM et al.
(1995)
The GM2 gangliosidoses.
In: Scriver CR,
Beaudet AL,
Sly WS and
Valle D (eds)
The Metabolic and Molecular Basis of Inherited Disease, vol.
2,
pp. 2839–2879.
New York: McGraw‐Hill.
Henrissat B and
Bairoch A
(1993)
New families in the classification of glycosyl hydrolases based on amino acid sequence similarities.
Biochemical Journal
293:
781–788.
Hou Y,
Vocadlo D,
Withers S et al.
(2000)
Role of beta Arg211 in the active site of human beta‐hexosaminidase B.
Biochemistry
39:
6219–6227.
Huang JQ,
Trasler JM,
Igdoura S et al.
(1997)
Apoptotic cell death in mouse models of GM2 gangliosidosis and observations on human Tay‐Sachs and Sandhoff diseases.
Human Molecular Genetics
6:
1879–1885.
Jeyakumar M,
Butters TD,
Cortina‐Borja M et al.
(1999)
Delayed symptom onset and increased life expectancy in Sandhoff disease mice treated with N‐butyldeoxynojirimycin.
Proceedings of the National Academy of Sciences of the USA
96:
6388–6393.
Kresse H,
Fuchs W,
Glossl J et al.
(1981)
Liberation of N‐acetylglucosamine‐6‐sulfate by human beta‐N‐acetylhexosaminidase A.
Journal of Biological Chemistry
256:
12926–12932.
Lemieux MJ,
Mark BL,
Cherney MM et al.
(2006)
Crystallographic structure of human beta‐hexosaminidase A: interpretation of Tay‐Sachs mutations and loss of G(M2) ganglioside hydrolysis.
Journal of Molecular Biology
359:
913–929.
Maegawa GH,
Banwell BL,
Blaser S et al.
(2009a)
Substrate reduction therapy in juvenile GM2 gangliosidosis.
Molecular Genetics and Metabolism
98:
215–224.
Maegawa GHB,
Tropak M,
Butner J et al.
(2007)
Pyrimethamine as a potential pharmacological chaperone for late‐onset forms of GM2 gangliosidosis.
Journal of Biological Chemistry
282:
9150–9161.
Maegawa GHB,
Tropak MB,
Buttner JD et al.
(2009b)
Identification and characterization of ambroxol as an enzyme‐enhancement agent for Gaucher disease.
Journal of Biological Chemistry
284:
23502–23516.
Mahuran DJ
(1998)
The GM2 activator protein, its roles as a co‐factor in GM2 hydrolysis and as a general glycolipid transport protein.
Biochimica et Biophysica Acta
1393:
1–18.
Mahuran DJ
(1999)
Biochemical consequences of mutations causing the GM2 gangliosidoses.
Biochimica et Biophysica Acta
1455:
105–138.
Maier T,
Strater N,
Schuette CG et al.
(2003)
The X‐ray crystal structure of human beta‐hexosaminidase B provides new insights into Sandhoff disease.
Journal of Molecular Biology
328:
669–681.
Mark BL,
Mahuran DJ,
Cherney MM et al.
(2003)
Crystal structure of human beta‐hexosaminidase B: understanding the molecular basis of Sandhoff and Tay‐Sachs disease.
Journal of Molecular Biology
327:
1093–1109.
Martin DR,
Krum BK,
Varadarajan GS et al.
(2004)
An inversion of 25 base pairs causes feline GM2 gangliosidosis variant.
Experimental Neurology
187:
30–37.
Ni M and
Lee AS
(2007)
ER chaperones in mammalian development and human diseases.
FEBS Letters
581:
3641–3651.
Pons T,
Olmea O,
Chinea G et al.
(1998)
Structural model for family 32 of glycosyl‐hydrolase enzymes.
Proteins
33:
383–395.
Shapiro BE,
Pastores GM,
Gianutsos J et al.
(2009)
Miglustat in late‐onset Tay‐Sachs disease: a 12‐month, randomized, controlled clinical study with 24 months of extended treatment.
Genetics in Medicine
11:
425–433.
Sharma R,
Deng H,
Leung A et al.
(2001)
Identification of the 6‐sulfate binding site unique to α‐subunit‐containing isozymes of human β‐hexosaminidase.
Biochemistry
40:
5440–5446.
Tews I,
Perrakis A,
Oppenheim A et al.
(1996)
Bacterial chitobiase structure provides insight into catalytic mechanism and the basis of Tay‐Sachs disease.
Nature Structural Biology
3:
638–648.
Triggs‐Raine BL,
Akerman BR,
Clarke JT et al.
(1991)
Sequence of DNA flanking the exons of the HEXA gene, and identification of mutations in Tay‐Sachs disease.
American Journal of Human Genetics
49:
1041–1054.
Trombetta ES and
Parodi AJ
(2003)
Quality control and protein folding in the secretory pathway.
Annual Review of Cell & Developmental Biology
19:
649–676.
Tropak MB,
Blanchard J,
Withers SG et al.
(2007)
High‐throughput screening for novel human lysosomal beta‐N‐acetyl hexosaminidase inhibitors acting as pharmacological chaperones.
Chemistry and Biology
14:
153–164.
Tropak MB,
Bukovac SW,
Rigat BA et al.
(2010)
A sensitive fluorescence‐based assay for monitoring GM2 ganglioside hydrolysis in live patient cells and their lysates.
Glycobiology
20:
356–365.
Tropak MB,
Kornhaber GJ,
Rigat BA et al.
(2008)
Identification of pharmacological chaperones for Gaucher disease and characterization of their effects on β‐glucocerebrosidase by hydrogen/deuterium exchange mass spectrometry.
ChemBioChem
9:
2650–2662.
Tropak MB and
Mahuran D
(2007)
Lending a helping hand, screening chemical libraries for compounds that enhance β‐hexosaminidase A activity in GM2 gangliosidosis cells.
FEBS Journal
274:
4951–4961.
Tropak MB,
Reid S,
Guiral M et al.
(2004)
Pharmacological enhancement of β‐hexosaminidase activity in fibroblasts from adult Tay‐Sach and Sandhoff patients.
Journal of Biological Chemistry
279:
13478–13487.
Wakamatsu N,
Kobayashi H,
Miyatake T et al.
(1992)
A novel exon mutation in human β‐hexosaminidase β subunit gene affecting the 3′ splice site selection.
Journal of Biological Chemistry
267:
2406–2413.
Wendeler M,
Werth N,
Maier T et al.
(2006)
The enzyme‐binding region of human GM2‐activator protein.
FEBS Journal
273:
982–991.
Williams SJ,
Mark BL,
Vocadlo DJ et al.
(2002)
Aspartate 313 in the Streptomyces plicatus hexosaminidase plays a critical role in substrate‐assisted catalysis by orienting the 2‐acetamido group and stabilizing the transition state.
Journal of Biological Chemistry
277:
40055–40065.
Wright CS,
Li SC and
Rastinejad F
(2000)
Crystal structure of human GM2‐activator protein with a novel beta‐cup topology.
Journal of Molecular Biology
304:
411–422.
Wu BM,
Tomatsu S,
Fukuda S et al.
(1994)
Overexpression rescues the mutant phenotype of L176F mutation causing beta‐glucuronidase deficiency mucopolysaccharidosis in two Mennonite siblings.
Journal of Biological Chemistry
269:
23681–23688.
Zarghooni M,
Bukovac S,
Tropak M et al.
(2004)
An alpha‐subunit loop structure is required for GM2 activator protein binding by beta‐hexosaminidase A.
Biochemical & Biophysical Research Communications
324:
1048–1052.
Further Reading
Ballabio A and
Gieselmann V
(2009)
Lysosomal disorders: from storage to cellular damage.
Biochimica et Biophysica Acta
1793:
684–696.
Bernales S,
Papa FR and
Walter P
(2006)
Intracellular signaling by the unfolded protein response.
Annual Review of Cell & Developmental Biology
22:
487–508.
Lee JH,
Yu WH,
Kumar A et al.
(2010)
Lysosomal proteolysis and autophagy require presenilin 1 and are disrupted by Alzheimer‐related PS1 mutations.
Cell
141:
1146–1158.
Settembre C,
Fraldi A,
Jahreiss L et al.
(2008)
A block of autophagy in lysosomal storage disorders.
Human Molecular Genetics
17:
119–129.
Vellodi A
(2005)
Lysosomal storage disorders.
British Journal of Haematology
128:
413–431.
Winslow AR and
Rubinsztein DC
(2008)
Autophagy in neurodegeneration and development.
Biochimica et Biophysica Acta
1782:
723–729.
Wiseman RL,
Powers ET,
Buxbaum JN et al.
(2007)
An adaptable standard for protein export from the endoplasmic reticulum.
Cell
131:
809–821.